Humanized tumor mice–a new cutting-edge model to study immune responses in advanced cancer therapy

2011 ◽  
Vol 49 (01) ◽  
Author(s):  
A Krömer ◽  
G Brockhoff ◽  
A Wege
2021 ◽  
Author(s):  
Rachna T Shroff ◽  
Pavani Chalasani ◽  
Ran Wei ◽  
Daniel Pennington ◽  
Grace Quirk ◽  
...  

Vaccines against SARS-CoV-2 have shown high efficacy, but immunocompromised participants were excluded from controlled clinical trials. We evaluated immune responses to the Pfizer/BioNTech mRNA vaccine in solid tumor patients (n=52) on active cytotoxic anti-cancer therapy. These responses were compared to a control cohort that also received the Pfizer/BioNTech vaccine (n=50). Using live SARS-CoV-2 assays, neutralizing antibodies were detected in 67% and 80% of cancer patients after the first and second immunizations, respectively, with a 3-fold increase in median titers after the booster. Similar trends were observed in serum antibodies against the receptor-binding domain (RBD) and S2 regions of Spike protein, and in IFN𝛾+ Spike-specific T cells. The magnitude of each of these responses was diminished relative to the control cohort. We therefore quantified RBD- and Spike S1-specific memory B cell subsets as predictors of anamnestic responses to viral exposures or additional immunizations. After the second vaccination, Spike-specific plasma cell-biased memory B cells were observed in most cancer patients at levels similar to those of the control cohort after the first immunization. These data suggest that a third immunization might elevate antibody responses in cancer patients to levels seen in healthy individuals after the second dose. Trials should be conducted to test these predictions.


2019 ◽  
Vol 203 (4) ◽  
pp. 789-794 ◽  
Author(s):  
Steve Oghumu ◽  
Sanjay Varikuti ◽  
James C. Stock ◽  
Greta Volpedo ◽  
Noushin Saljoughian ◽  
...  

Cancer ◽  
2020 ◽  
Vol 126 (16) ◽  
pp. 3750-3757
Author(s):  
Kenneth Mah ◽  
Nadia Swami ◽  
Lisa W. Le ◽  
Ronald Chow ◽  
Breffni L. Hannon ◽  
...  

2003 ◽  
Vol 170 (4) ◽  
pp. 1611-1614 ◽  
Author(s):  
Anirban Bose ◽  
Yoshihiko Inoue ◽  
Kenneth E. Kokko ◽  
Fadi G. Lakkis

2006 ◽  
Vol 176 (8) ◽  
pp. 4520-4524 ◽  
Author(s):  
Ken Takahashi ◽  
Taro Kawai ◽  
Himanshu Kumar ◽  
Shintaro Sato ◽  
Shin Yonehara ◽  
...  

2017 ◽  
Vol 45 ◽  
pp. 16-20 ◽  
Author(s):  
Jian Qiao ◽  
Haidong Tang ◽  
Yang-Xin Fu

2017 ◽  
Vol 32 (4) ◽  
pp. 775-785 ◽  
Author(s):  
Kristel Paque ◽  
Monique Elseviers ◽  
Robert Vander Stichele ◽  
Koen Pardon ◽  
Marianne J Hjermstad ◽  
...  

Background: Information on medication use in the last months of life is limited. Aim: To describe which medications are prescribed and deprescribed in advanced cancer patients receiving palliative care in relation to time before death and to explore associations with demographic variables. Design: Prospective study, using case report forms for monthly data collection. Medication included cancer treatment and 19 therapeutic groups, grouped into four categories for: (1) cancer therapy, (2) specific cancer-related symptom relief, (3) other symptom relief and (4) long-term prevention. Data were analysed retrospectively using death as the index date. We compared medication use at 5, 4, 3, 2 and 1 month(s) before death by constructing five cross-sectional subsamples with medication use during that month. Paired analyses were done on a subsample of patients with at least two assessments before death. Setting/participants: We studied the medication use of 720 patients (mean age 67, 56% male) in 30 cancer centres representing 12 countries. Results: From 5 to 1 month(s) before death, cancer therapy decreased (55%–24%), most medications for symptom relief increased, for example, opioids (62%–81%) and sedatives (35%–46%), but medication for long-term prevention decreased (38%–27%). The prevalence of chemotherapy was 15.5% in the last month of life, with 9% of new courses started in the last 2 months. With higher age, chemotherapy and opioid use decreased. Conclusion: Medications for symptom relief increased in almost all medication groups. Deprescribing was found in heart medication/anti-hypertensives and cancer therapy, although use of the latter remained relatively high.


Sign in / Sign up

Export Citation Format

Share Document